Detailed analysis of Vigabatrin (Vigabatrin) and its safety during pregnancy

Vigabatrin (Vigabatrin) is an antiepileptic drug used to treat refractory epilepsy, such as infantile spasms and refractory focal epilepsy. It exerts sedative and anti-epileptic effects by inhibiting GABAaminase, thereby increasing GABA (γ-aminobutyric acid) concentration in the brain. However, there has been considerable clinical controversy regarding the safety of Vigabatrin used by pregnant women, and special caution is required.

First of all, animal experiments show that Vigabatrin may cause certain toxicity to the fetus at high doses, including growth retardation and structural abnormalities. In human pregnancy studies, although data are relatively limited, there have been individual case reports suggesting that Vigabatrin use may be associated with neonatal developmental abnormalities (such as structural heart abnormalities or facial malformations). Therefore, it is classified as an FDA Pregnancy Category C drug, meaning it has been shown to have adverse effects on the fetus in animal studies but has not been adequately studied in humans and should only be considered for use if the potential benefits outweigh the risks.

Secondly,VigabatrinThe most concerning side effect is irreversible visual field loss, which not only affects the quality of life of the pregnant woman, but may also affect her ability to care for her newborn. Use during pregnancy may increase the risk of this adverse reaction, especially when the dose is larger or used for a long time. Therefore, if Vigabatrin must be used during pregnancy, periodic visual field examinations should be performed and any changes in vision should be closely monitored.

In summary, vigabatrin should be used with great caution during pregnancy and should only be considered when there is no other alternative treatment and the condition must be controlled. Before deciding whether to take medication, pregnant women should fully communicate with epilepsy specialists and obstetricians, evaluate the pros and cons of medication, and develop an individualized treatment plan. If pregnancy is planned, it is best to re-evaluate the anti-epileptic regimen before pregnancy and try to choose safer alternatives. At the same time, prenatal screening and postpartum follow-up should be strengthened to ensure the safety of mothers and infants.

Reference materials:https://www.drugs.com/